CClinicalTrials.gg
CompletedNCT03447158Updated Jan 27, 2020

Effects of Hyperosmolar Dextrose in Rotator Cuff Disorder With Bursitis

An interventional study of 15% Dextrose and Normal saline in Subacromial Bursitis, sponsored by Mackay Memorial Hospital. Completed at 1 site in Taiwan. Open to participants aged 20 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-01-27.

Sponsored by Mackay Memorial Hospital · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
20 Years to 65 Years
Sex
All
01

Study summary

The main purpose of this study is to compare treatment efficacy of different concentration dextrose injection in chronic subacromial bursitis .

Read the detailed description

Rotator cuff disorder with bursitis is one of the most frequent pathologies of the shoulder, which may cause serious restriction of daily activities and reduce quality of life. There are many ways in treating rotator cuff disorder with bursitis, including medication, physical therapy, kinesiological taping, acupuncture and local injection. Protholotherapy, which inject hyperosmolar dextrose to soft tissue, is a novel management in musculoskeletal disorders. However, only few trials exist in studying hyperosmolar dextrose injection for rotator cuff disorder with bursitis and most of them have small sample size and not randomized. The aim of this study was to figure out the effects of sonographically guided subacromial bursa injection with hyperosmolar dextrose in rotator cuff disorder with bursitis by a randomized controlled trial.

02

Conditions studied

  • Subacromial Bursitis

Browse trials for

03

Who can participate

Ages eligible
20 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  1. 20-65 years-old
  2. pain lasting >3 months
  3. Painful arc between 40° to 120° in abduction
  4. positive Neer and Hawkins-Kennedy tests
  5. positive Empty can test
  6. pain in daily living activities
  7. Bursa thickness more than 2mm in ultrasound
  8. Rotator cuff tendinopathy

Exclusion criteria

Exclusion Criteria:

  1. history of significant shoulder trauma
  2. history of surgery, fracture, or dislocation
  3. adhesive capsulitis
  4. full thickness rotator cuff tear
  5. a long head of bicep tendon tear
  6. Contra-indications to local dextrose injection (known blood coagulation disorders, warfarin therapy, allergy to dextrose)
  7. previous shoulder steroid injection in one month
  8. had any rheumatologic, systemic, or neurologic disorders
  9. patients taking regular systemic NSAIDs or steroids
  10. pregnant or breastfeeding mothers
  11. malignancy
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    15% Dextrose group

    4.5cc 15% dextrose and 0.5cc 1% xylocaine was injected into inflamed subacromial bursa under sonographically guidance

    Procedure: 15% Dextrose

  • Placebo comparator
    control group

    4.5cc normal saline and 0.5cc 1% xylocaine was injected into inflamed subacromial bursa under sonographically guidance

    Procedure: Normal saline

Interventions

  • Procedure15% Dextrose

    inject 15% dextrose and xylocaine into subacrominal bursa under sonographically guidance

  • ProcedureNormal saline

    inject normal saline and xylocaine into subacrominal bursa under sonographically guidance

05

What researchers measure

Primary outcomes

  1. Change from Baseline pain on activity at 1 week, 1 month, and 3 months after 3rd section of therapy

    maximal visual analog scale (VAS) in the past week during shoulder activity. Visual analog scale is range from 0-10. The higher score indicated more severe pain.

    Time frame: before therapy sections, 1 week, 1 month, and 3 months after 3rd section of therapy

Secondary outcomes

  1. Change from Baseline shoulder joint active range of motion (PROM) at 1 week, 1 month, and 3 months after 3rd section of therapy

    abduction and flexion

    Time frame: before therapy sections, 1 week, 1 month, and 3 months after 3rd section of therapy

  2. Change from Baseline Shoulder Pain and Disability Index (SPADI) score at 1 week, 1 month, and 3 months after 3rd section of therapy

    Shoulder pain and disability questionnaire with two subscales, pain scale and function scale. Pain scale is range from 0-50. The higher scale indicates worse pain outcome. Function scale is range from 0-80. The higher scale indicates poor shoulder function. The total scale is summation of pain scale and function scale.

    Time frame: before therapy sections, 1 week, 1 month, and 3 months after 3rd section of therapy

  3. Change from Baseline Ultrasound property at 1 week, 1 month, and 3 months after 3rd section of therapy

    Thickness of bursa and elastogram

    Time frame: before therapy sections, 1 week, 1 month, and 3 months after 3rd section of therapy

  4. Change from Baseline pain on resting at 1 week, 1 month, and 3 months after 3rd section of therapy

    maximal visual analog scale (VAS) in the past week during resting. Visual analog scale is range from 0-10. The higher score indicated more severe pain.

    Time frame: before therapy sections, 1 week, 1 month, and 3 months after 3rd section of therapy

06

Study locations

1 site
  • MacKay Memorial Hospital
    Taipei, Taiwan
07

References and documents

Publications

  • Chang YJ, Chang FH, Hou PH, Tseng KH, Lin YN. Effects of Hyperosmolar Dextrose Injection in Patients With Rotator Cuff Disease and Bursitis: A Randomized Controlled Trial. Arch Phys Med Rehabil. 2021 Feb;102(2):245-250. doi: 10.1016/j.apmr.2020.08.010. Epub 2020 Sep 11. PubMed 32926850 ↗
08

Registry details

Key details

Study ID
NCT03447158
Lead sponsor
Mackay Memorial Hospital
Responsible party
Sponsor
First posted
Feb 27, 2018
Start date
Jul 18, 2018
Primary completion
Sep 25, 2019
Completion
Jan 23, 2020
Last update
Jan 27, 2020

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion